奥沙利铂或伊立替康联合5-FU/LV治疗晚期结直肠癌的荟萃分析

目的:评价奥沙利铂联合氟尿嘧啶/亚叶酸钙(5-FU/LV)方案与伊立替康联合5-FU/LV方案治疗晚期结直肠癌的疗效与毒副作用的差异。方法:在PubMed数据库和CHKD数据库上检索2组方案治疗晚期结直肠癌的随机对照试验,采用荟萃分析专用软件Review Manager version4.2.2进行系统评价。结果:共有6个研究纳入系统评价。在总缓解率上奥沙利铂组高于伊立替康组(RR=0.82,95%CI为0.74～0.91);伊立替康组中性粒细胞减少发生率低于奥沙利铂组(RR=0.79,95%CI为0.69～0.90),在恶心/呕吐和腹泻的发生率上高于奥沙利铂组(RR=1.85,95%CI为1.42～2.40;RR=1.75,95%CI为1.41～2.17)。结论:奥沙利铂联合5-FU/LV方案在晚期结直肠癌的治疗中优于伊立替康联合5-FU/LV方案。

Meta-analysis of Oxaliplatin or Irinotecan Combined with 5-FU/LV for Advanced Colorectal Cancer

OBJECTIVE：To evaluate clinical efficacy and toxicities of oxaliplatin or irinotecan combined with 5-FU/LV for advanced colorectal cancer. METHODS：RCTs were retrieved from PubMed database and CHKD and Metaanalysis was carried out using Review Manager version 4.2.2 software. RESULTS：Six studies were enrolled. The oxaliplatin group was superior to irinotecan group in the overall response rate（RR=0.82,95%CI ranged from 0.74 to 0.91）. The incidence rate of neutropenia in irinote-can group was lower than in oxaliplatin group（RR=0.79,95%CI ranged from 0.69 to 0.90）while the incidence of nausea/vomiting and diarrhea in irinotecan group was higher than in oxaliplatin group（RR=1.85,95%CI ranged from 1.42 to 2.40;RR=1.75, 95%CI ranged from 1.41 to 2.17）. CONCLUSION：The scheme oxaliplatin combined with 5-FU/LV in the treatment of advanced colorectal cancer is superior to the scheme irinotecan combined with 5-FU/LV.